Skip to main content

Animations

MJFF Publications

4601 - 4610 of 6403 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2024
  • 2018
  • 2021
  • 2016
  • 2024
  • 2024
  • 2010
  • 2022
  • Summary Details
    OPEN
    Title: Small molecule C381 targets the lysosome to reduce inflammation and ameliorate disease in models of neurodegeneration
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1073/pnas.2121609119
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Closed-Loop Deep Brain Stimulation to Treat Medication-Refractory Freezing of Gait in Parkinson’s Disease
    Journal Name: Frontiers in Human Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnhum.2021.633655
    Citation Count: 37
  • Summary Details
    OPEN
    Title: Development and characterization of phospho-ubiquitin antibodies to monitor PINK1-PRKN signaling in cells and tissue
    Journal Name: Autophagy
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1080/15548627.2024.2356490
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Exploring variability in basal ganglia connectivity with functional MRI in healthy aging
    Journal Name: Brain Imaging and Behavior
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s11682-018-9824-1
    Citation Count: 24
  • Summary Details
    OPEN
    Title: Novel Thienopyrimidine-Based PET Tracers for P2Y12 Receptor Imaging in the Brain
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1021/acschemneuro.1c00641
    Citation Count: 26
  • Summary Details
    OPEN
    Title: α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology
    Journal Name: Journal of Neuroinflammation
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12974-016-0532-8
    Citation Count: 33
  • Summary Details
    OPEN
    Title: Pathways controlling neurotoxicity and proteostasis in mitochondrial complex I deficiency
    Journal Name: Human Molecular Genetics
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1093/hmg/ddae018
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-024-49016-3
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Bioactivity of AAV2‐neurturin gene therapy (CERE‐120): Differences between Parkinson's disease and nonhuman primate brains
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.23442
    Citation Count: 167
  • Summary Details
    OPEN
    Title: Putting participants and study partners FIRST when clinical trials end early
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/alz.12732
    Citation Count: 9
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.